D&A at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edgewise Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edgewise Therapeutics, Inc.'s D&A?
- Edgewise Therapeutics, Inc. (EWTX) reported D&A of $537K in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s D&A changed year-over-year?
- Edgewise Therapeutics, Inc.'s D&A increased by 4.7% year-over-year, from $513K to $537K.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s D&A has grown at a 60.4% compound annual growth rate (CAGR), from $308K to $2.04M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.